TAP brings together distributed networks of researchers, clinicians, computational scientists, and industry operators — connected by shared infrastructure, AI systems, and capital — to advance critical work in life sciences at a pace and efficiency that conventional structures cannot match.
Our team has worked across national laboratories, Operation Warp Speed, and the full spectrum of pharmaceutical R&D — from early discovery through clinical translation and regulatory clearance. We have deep experience with what it takes to move science from idea to impact, and we have built the organizational and financial infrastructure to do it repeatedly.
We engage partners by referral and work selectively across drug discovery, biomarker development, clinical design, and detection technologies.
Discovery at the frontier of biology is a data sparsity problem, not a compute problem. TAP keeps experienced biologists at the center of every program — setting the hypotheses, interpreting ambiguous signals, and committing empirical resources where judgment matters most. AI accelerates the search and compresses experimental cycles; biologists navigate where data cannot yet speak for itself.
Extraction of richer features from imaging studies using AI and deep subject matter expertise. Development of biomarkers — including neuroinflammation and other elusive targets — to better understand pathologies and pave the way for better treatment selection and clinical trial design.
Institutional-grade portfolio management applied to early-stage research. Dynamic allocation across multiple disciplines and candidates, with data-enabled decision-making throughout the life of each program.
AI surfaces patterns, generates hypotheses, and tightens empirical feedback loops — but biological insight remains the decision-making layer. Our model is human-machine teaming at every step: AI extends the reach of each scientist's judgment, and that balance evolves as data deepens and AI capabilities mature.
Special Assistant to the President, Biological Threats • Managing Director/Partner, BCG, PwC • Operation Warp Speed architect
Senior Pharma Leadership • AI-driven Drug Discovery, Portfolio • Platform Technology and Science, GSK
Senior Pharma Leadership • Collaborative Drug Discovery, InnoCentive • R&D Executive, Eli Lilly
Head of Operations, SaponiQx • Novavax Vaccine Lead, US Government Operation Warp Speed • Technology Selection and Clinical Evaluation, Department of Defense
Physician Executive & Software Engineer • Chief Medical Officer, United Healthcare, VA • Faculty, Harvard Medical School
DNA Encoded Libraries • Informatics & Molecular Biology, Dice Therapeutics
Machine Learning, Computational Biology, Cancer Genomics • CSO / CTO, Cancer IQ
Machine Learning, Deep Learning • AI Researcher/Instructor, Berkeley, NASA • Founder, Silicon Valley Bank AI Lab
Professor of Neurobiology & Behavior, UC Irvine • Director, UCI Brain Initiative • Co-Founder, Augnition Labs & Enthorin Therapeutics • Memory, neuroimaging & cognitive decline • PhD, UC Irvine
TAP Neuro
Scientific Co-Founder, TAP Neuro (Alzheimer's Disease) • Professor, Harvard Medical School & MGH • Associate Member, Broad Institute of MIT & Harvard • Principal Faculty, Harvard Stem Cell Institute • Memory circuits, neurogenesis & cognitive restoration